Last reviewed · How we verify
Fixed dose - Stavudine, lamivudine and Nevirapine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Fixed dose - Stavudine, lamivudine and Nevirapine (Fixed dose - Stavudine, lamivudine and Nevirapine) — University of Zimbabwe.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fixed dose - Stavudine, lamivudine and Nevirapine TARGET | Fixed dose - Stavudine, lamivudine and Nevirapine | University of Zimbabwe | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fixed dose - Stavudine, lamivudine and Nevirapine CI watch — RSS
- Fixed dose - Stavudine, lamivudine and Nevirapine CI watch — Atom
- Fixed dose - Stavudine, lamivudine and Nevirapine CI watch — JSON
- Fixed dose - Stavudine, lamivudine and Nevirapine alone — RSS
Cite this brief
Drug Landscape (2026). Fixed dose - Stavudine, lamivudine and Nevirapine — Competitive Intelligence Brief. https://druglandscape.com/ci/fixed-dose-stavudine-lamivudine-and-nevirapine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab